Showing 1 - 19 results of 19 for search 'Hans Tesch', query time: 3.10s Refine Results
  1. 1
    P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    P679: SPOTLIGHT ON THE REAL-WORLD TREATMENT OF CML PTS IN GERMANY: A RETROSPECTIVE SURVEY IN PRIVATE ONCOLOGY PRACTICES
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study
    by Markus Wallwiener, Naiba Nabieva, Manuel Feisst, Tanja Fehm, Johann de Waal, Mahdi Rezai, Bernd Baier, Gerold Baake, Hans-Christian Kolberg, Martin Guggenberger, Mathias Warm, Nadia Harbeck, Rachel Wuerstlein, Jörg-Uwe Deuker, Peter Dall, Barbara Richter, Grischa Wachsmann, Cosima Brucker, Jan Willem Siebers, Milos Popovic, Thomas Kuhn, Christopher Wolf, Hans-Walter Vollert, Georg-Peter Breitbach, Wolfgang Janni, Robert Landthaler, Andreas Kohls, Daniela Rezek, Thomas Noesselt, Gunnar Fischer, Stephan Henschen, Thomas Praetz, Volker Heyl, Thorsten Kühn, Thomas Krauss, Christoph Thomssen, Andre Hohn, Hans Tesch, Christoph Mundhenke, Alexander Hein, Claudia Rauh, Christian M. Bayer, Katja Schmidt, Erik Belleville, Sara Y. Brucker, Peyman Hadji, Matthias W. Beckmann, Diethelm Wallwiener, Sherko Kümmel, Andreas Hartkopf, Peter A. Fasching
    Published 2019-06-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Interest in Integrative Medicine Among Postmenopausal Hormone Receptor–Positive Breast Cancer Patients in the EvAluate-TM Study
    by Carolin C. Hack MD, Peter A. Fasching MD, Tanja Fehm MD, Johann de Waal MD, Mahdi Rezai MD, Bernd Baier MD, Gerold Baake MD, Hans-Christian Kolberg MD, Martin Guggenberger MD, Mathias Warm MD, Nadia Harbeck MD, Rachel Wuerstlein MD, Jörg-Uwe Deuker MD, Peter Dall MD, Barbara Richter MD, Grischa Wachsmann MD, Cosima Brucker MD, Jan W. Siebers MD, Nikos Fersis MD, Thomas Kuhn MD, Christopher Wolf MD, Hans-Walter Vollert MD, Georg-Peter Breitbach MD, Wolfgang Janni MD, Robert Landthaler MD, Andreas Kohls MD, Daniela Rezek MD, Thomas Noesslet MD, Gunnar Fischer MD, Stefan Henschen MD, Thomas Praetz MD, Volker Heyl MD, Thorsten Kühn MD, Thomas Krauss MD, Christoph Thomssen MD, Andre Hohn MD, Hans Tesch MD, Christoph Mundhenke MD, Alexander Hein MD, Claudia Rauh MD, Christian M. Bayer MD, Adib Jacob, Katja Schmidt PhD, Erik Belleville PhD, Peyman Hadji MD, Sara Y. Brucker MD, Diethelm Wallwiener MD, Sherko Kümmel MD, Matthias W. Beckmann MD, Daniela Paepke MD
    Published 2017-06-01
    Get full text
    Article
    Save to List
    Saved in:
Search Tools: RSS Feed – Email Search